Skip to content
value.today
Ainos, Inc. logo

Ainos, Inc.

AIMD
$6 Mmarket cap on Oct 26, 2026-38.7% since Jan 2024
Compare
World rank
#26,616
Revenue
$0 M
For year ending December-2025
Net income
$-15 M
-12308.3% margin
SEC filing
Employees
41
As of December 31, 2025
SEC filing

Ainos, Inc. in brief

Ainos, Inc. is a listed company in the Biotechnology industry, based in Houston, Texas, USA. Its market value was $6 M on 26 October 2026, which makes it the 26,616th largest listed company in the world and the 4,373rd largest in the USA on this site. In the year to December 2025 it had sales of $0 M and a net loss of $15 M. It employs about 41 people and Chun-Hsien Tsai is its chief executive. Its shares trade under the symbol AIMD (Nasdaq).

Written from the figures on this page, so it changes when they do. The date of each figure is under How current the figures are.

About Ainos, Inc.

Ainos, Inc., incorporated in the State of Texas in 1984, is a dual-platform company advancing artificial intelligence–based smelltech technologies and immune therapeutics. Our primary strategic focus is the commercialization of our proprietary scent digitization platform, AI Nose, while we also continue to develop therapeutic assets based on our low-dose oral interferon program, VELDONA®.

Our core technology platform, AI Nose, is an AI-based electronic olfaction system that integrates gas sensor arrays with proprietary artificial intelligence models, which we refer to as a smell language model, to digitize scent and volatile organic compound signals into Smell ID, a machine-readable data format. AI Nose is initially developed in healthcare-related settings, including point-of-care testing. These early healthcare applications shaped the platform’s sensor architecture, data models, and system calibration.

From the company's annual report filed with the US SEC: read the report

Ainos, Inc. timeline

3 events, 1996–2022
  1. 1996
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2021
  4. ✎
    Renamed Ainos, Inc.
    Formerly Amarillo Biosciences Inc.
  5. 2022
  6. 💰
    Record revenue of $4 million
    FY2022, the highest of the 7 years on record.

Events of Ainos, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$24 M$48 M$72 M$96 M2023202420252026

World rank over time

▼ down 3,337 places since 2022
2022-01-07: #23281#23,28120222022-12-25: #30743#30,74320222023-07-30: #29469#29,46920232024-01-05: #31050#31,05020242026-03-08: #12746#12,74620262026-08-01: #22740#22,74020262026-10-09: #26147#26,14720262026-10-26: #26618#26,6182026

Rank in USA: #4,501 (Jan 2022) · #5,472 (Dec 2022) · #5,183 (Jul 2023) · #4,517 (Jan 2024) · #2,378 (Mar 2026) · #4,020 (Aug 2026) · #4,276 (Oct 2026) · #4,372 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
51.1×
Price / book
0.8×
Free cash flow yield
-75.7%
Net margin
-12308.3%
Operating margin
-11658.3%
Return on equity
-195.4%
Liabilities / assets
63.8%
Revenue growth
0.0%
R&D / revenue
6458.3%
Revenue per employee
$3 K
Profit per employee
$-360 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $0M, net income $-1M$0MFY18Fiscal year ending Dec 2019: revenue $0M, net income $-2M$0MFY19Fiscal year ending Dec 2020: revenue $0M, net income $-1M$0MFY20Fiscal year ending Dec 2021: revenue $1M, net income $-4M$1MFY21Fiscal year ending Dec 2022: revenue $4M, net income $-14M$4MFY22Fiscal year ending Dec 2023: revenue $0M, net income $-14M$0MFY23Fiscal year ending Dec 2024: revenue —, net income $-15M—FY24Fiscal year ending Dec 2025: revenue $0M, net income $-15M$0MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$0M—$-14M$-15M-12308.3%
Dec 2024——$-14M$-15M—
Dec 2023$0M-96.6%$-13M$-14M-11475.0%
Dec 2022$4M+496.6%$-14M$-14M-398.0%
Dec 2021$1M+2850.0%$-4M$-4M-659.3%
Dec 2020$0M+100.0%$-1M$-1M-7250.0%
Dec 2019$0M-87.5%$-2M$-2M-15800.0%
Dec 2018$0M—$-1M$-1M-1675.0%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-5M$0M$-5M$-3.46—
Dec 2024$-6M$0M$-6M$-7.82—
Dec 2023$-5M$0M$-5M$-3.36—
Dec 2022$-3M$1M$-4M——
Dec 2021$-1M$0M$-1M$-0.03—
Dec 2020$-1M$0M$-1M$-0.04—
Dec 2019$-1M$0M$-1M$-0.04—
Dec 2018$-1M$0M$-1M$-0.04—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-5M—Dec ’24Three months to Mar 2025: revenue $0M, net income $-3M$0MMar ’25Three months to Jun 2025: revenue $0M, net income $-4M$0MJun ’25Three months to Sep 2025: revenue $0M, net income $-3M$0MSep ’25Three months to Dec 2025 (from the annual report): revenue $0M, net income $-4M$0MDec ’25Three months to Mar 2026: revenue $0M, net income $-2M$0MMar ’26Three months to Jun 2026: revenue $0M, net income $-5M$0MJun ’26Three months to Sep 2026: revenue $1M, net income $-2M$1MSep ’26

Latest quarter to Sep 2026: revenue $1M, net income $-2M. Lighter bars: fourth quarters worked out from the annual report.

SEC filings

Official filings of Ainos, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$0 M
Operating income
$-14 M
Net income
$-15 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$21 M
Total liabilities
$13 M
Total equity
$8 M

As of December-2025

Top 15 institutional investors in Ainos, Inc.#

As of Sep 30, 2026
15 institutions held 204,817 shares (about 2.8% of the shares outstanding) on Sep 30, 2026. The ten largest hold 2.7%. Filings read through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 15 largest institutional investors in Ainos, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Geode Capital Management, LLC43,892-194 (-0.44%)0.59%$0 MNov 6, 2026
2Vanguard Capital Management LLC33,939+17,915 (+111.80%)0.46%$0 MNov 13, 2026
3Principal Securities, Inc.31,596New0.43%$0 MNov 12, 2026
4Envestnet Asset Management Inc31,596New0.43%$0 MNov 16, 2026
5Keystone Financial Group25,250-300 (-1.17%)0.34%$0 MNov 12, 2026
6Mariner, LLC15,8000 (0.00%)0.21%$0 MNov 12, 2026
7Vanguard Fiduciary Trust Co14,1690 (0.00%)0.19%$0 MNov 13, 2026
8BlackRock, Inc.3,0650 (0.00%)0.04%$0 MNov 13, 2026
9Citigroup Inc1,702+1,525 (+861.58%)0.02%$0 MNov 4, 2026
10Tower Research Capital LLC (TRC)1,683-1,474 (-46.69%)0.02%$0 MNov 16, 2026
11Steward Partners Investment Advisory, LLC1,2080 (0.00%)0.02%$0 MNov 13, 2026
12Seneschal Advisors, LLC900-900 (-50.00%)0.01%$0 MNov 13, 2026
13Caitong International Asset Management Co., Ltd12-81 (-87.10%)0.00%$0 MOct 29, 2026
14Barclays PLC3New0.00%$0 MNov 6, 2026
15UBS Group AG2-4,590 (-99.96%)0.00%$0 MNov 10, 2026

Mutual funds holding Ainos, Inc.#

4 funds hold shares worth $0 M (about 0.9% of the company). Since their previous reports 3 added shares and 0 sold, buying $0 M net.
Mutual funds holding Ainos, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC48,596$0 M0.66%<0.01%+131%May 31, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.16,024$0 M0.22%<0.01%+73%Jun 30, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC2,049$0 M0.03%<0.01%+68%May 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC396$0 M<0.01%<0.01%no changeMay 31, 2026

As of Jun 30, 2026

Insider trading at Ainos, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$21 K
9 purchases, 1 insider
Sold, 12 months
$490 K
9 sales, 3 insiders
Net, 12 months
-$469 K
open market only
Insiders on file
22
since
$11 K-$388 K$0Jun 2025: bought $0 (1 trades), sold $24 K (7 trades)Jun 25Jul 2025: bought $0 (0 trades), sold $39 K (2 trades)Aug 2025: bought $0 (0 trades), sold $86 K (2 trades)AugSep 2025: bought $0 (0 trades), sold $4 K (1 trades)Oct 2025: bought $0 (0 trades), sold $38 K (3 trades)OctJan 2026: bought $0 (0 trades), sold $102 K (3 trades)Apr 2026: bought $511 (2 trades), sold $0 (0 trades)AprMay 2026: bought $9 K (5 trades), sold $388 K (6 trades)Jun 2026: bought $11 K (2 trades), sold $0 (0 trades)Jun
Bought (open market)Sold (open market)Hover a month for the totals
Ainos, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Yao-Chung ChiangDirectorBuyindirect+3,500$2.050$7 K11,279Form 4
filed Yao-Chung ChiangDirectorBuyindirect+2,000$2.130$4 K7,779Form 4
filed Yao-Chung ChiangDirectorBuyindirect+250$2.300$5755,779Form 4
filed Yao-Chung ChiangDirectorBuyindirect+2,000$2.000$4 K5,529Form 4
filed Taiwan Carbon Nano Technology Corp10% ownerSell-41,000$2.360$97 K948,925Form 4
filed Ting-Chuan LeeDirectorSell-109,988$1.900$209 K807,417Form 4
filed Chun-Jung TsaiDirectorSell-27,718$1.870$52 K658,199Form 4
filed Chun-Jung TsaiDirectorSell-1,082$1.550$2 K685,917Form 4

Markets and events: Ainos, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
37,529
0.6% of shares · 1.4 days to cover
Buybacks, Q4 2013
$0M
Q4 2013
Shares sold short, last 24 reportsAll stocks →

Bankruptcy filing: (8-K); (8-K); (8-K); (8-K); (8-K)

Ainos, Inc. share buybacks by quarter
Buybacks, quarterFiscalSpent
Q4 2013Q4 2013$0M

Trading halts

  • 2026-11-12 20:20 UTC, code LUDP, resumed 20:25 UTC
  • 2026-11-12 17:06 UTC, code LUDP, resumed 17:11 UTC
  • 2026-11-12 17:00 UTC, code LUDP, resumed 17:05 UTC
  • 2026-11-12 16:54 UTC, code LUDP, resumed 16:59 UTC
  • 2026-11-12 16:41 UTC, code LUDP, resumed 16:51 UTC

Fails to deliver

  • : 83 shares at $0.81
  • : 83 shares at $0.84
  • : 78 shares at $0.88
  • : 79 shares at $0.90
  • : 675 shares at $0.93

Ainos, Inc. scorecard#

Passes 2 of the 14 checks that could be worked out: strongest in financial health (1 of 3), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 26, 2026.

  • Valuation1 of 5
  • Growth0 of 2
  • Profitability0 of 3
  • Financial health1 of 3
  • Shareholder returns0 of 1

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 20, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Ainos, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Ainos, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue124211223,520595171278251—
Cost of revenue21533762,114184118.86560—
Gross profit103−32−2541,4054105.33.013191—
Research and development7,7508,4147,3176,8461,9210.45333——
Selling, general and administrative6,3445,3955,6358,5362,3571,4451,5311,315770667
Operating expenses14,09313,80912,95315,3824,2781,4461,5831,348770—
Operating income−13,990−13,841−13,206−13,976−3,867−1,440−1,580−1,335−580−667
Interest expense and finance costs7126161445419r11—4.0382.9
Other non-operating income (expense)−780−1,021−563−30−21—————
Income before tax−14,770−14,862−13,770−14,007−21−10————
Income tax0.80.80.80—00——0
Net income including minority interests———14,0073,889—————
Net income attributable to shareholders−14,771−14,863−13,771−14,007−3,889−1,451−1,581−1,339−617−670
Earnings per share, basic-3.46-7.82r-3.36—-0.03-0.04-0.04-0.04-0.03-0.03
Earnings per share, diluted-3.46-7.82r-3.36—-0.03-0.04-0.04-0.04-0.03-0.03
Shares, weighted average (basic)4.31.9r4.1———————
Shares, weighted average (diluted)4.31.9r4.1—1134140362320r
Balance sheet
Cash and cash equivalents4173,8931,8861,8531,751224091,2772,038r134
Receivables0.00.10.520200————
Inventory2961441685950r0r4.1—2315
Other current assets4263014201964665132r272476
Current assets1,1394,3382,4732,8462,21876445r1,3032,084262
Property, plant and equipment3435608771,3761,1883.25.1r142744
Other intangible assets19,22623,74828,28332,80737,329181146146182156
Total assets20,87128,82031,84237,10940,8222605971,4642,294463
Accounts payable—————146209115159169r
Current liabilities1,0793,9551,3372,47330,5951,0997537341,8231,273
Lease liabilities (non-current)———8.130—————
Non-current liabilities————300————
Total liabilities13,30913,3047,3942,48130,6251,0997537341,8231,273
Retained earnings−67,520−52,749−37,886−24,116−10,109−6,220−4,770−3,188−1,884−1,267
Shareholders' equity7,56315,51624,44834,62810,197−838−157730471r−810
Total equity—————−838−157730471—
Total liabilities and equity20,87128,82031,84237,10940,8222605971,4642,294463
Shares outstanding5.8r3.1r4.74.0r9.6r4241392322
Cash-flow statement
Depreciation and amortization4,7804,8024,8714,8332,0441522564026
Share-based compensation1,7283,5431,1156,422−11r15001001060
Cash from operating activities−4,615−5,808−4,695−3,041r−1,250−500−909−1,009−485r−521
Capital expenditure−35−21−93−634−1440−1.6−4.9—−48
Intangible assets bought————−5,773−7.2−11−2.4−49−101
Cash from investing activities−2.2−125−102−630−181−7.2−13−7.3−49−148
Shares issued————46,0000————
Cash from financing activities1,0088,0264,9243,851r3,154120552552,438782
Exchange-rate effect on cash————5.40————
Change in cash−3,4762,007321021,729r−387−868−7611,904r113
Report10-K10-K10-K10-K10-K10-K/A10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

As of Sep 30, 2026

Executive pay at Ainos, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$916 K
Chun-Hsien Tsai
Other top executives, average
$325 K
the CEO earned 2.8× this
$100 invested is now
—
Ainos, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Chun-Hsien Tsai$916 K$2.2 M$325 K—
2024Chun-Hsien Tsai$302 K$21 K$72 K—
2023Chun-Hsien Tsai$1.3 M$987 K$161 K—
2022Chun-Hsien Tsai$3.8 M$778 K$850 K—
2021Chun-Hsien Tsai$63 K$63 K$201 K$394

As of Dec 31, 2025

Events at Ainos, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling
  • Auditor changedFiling
  • Auditor changedFiling

Delisting notice 1 · Auditor changed 2 · Material agreement 5 · New debt 1 · Unregistered share sale 1 · Bylaws or fiscal year changed 2 · Shareholder vote 1 · Results announced 8

Ainos, Inc.: events reported to the SEC
FiledWhat happenedFiling
Delisting notice8-K
Material agreement8-K
Results announced8-K
Bylaws or fiscal year changed8-K
Material agreement8-K
Results announced8-K
Auditor changed8-K
New debt8-K
Results announced8-K
Results announced8-K
Unregistered share sale8-K
Shareholder voteResults announced8-K
Material agreement8-K
Results announced8-K
Auditor changed8-K
Bylaws or fiscal year changed8-K
Results announced8-K
Material agreement8-K
Material agreement8-K
Results announced8-K

As of Nov 20, 2026

Acquisitions and funding#

Private share sales · funding history

Private share sales of Ainos, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Apr 2021$20 MPrivate placement after listing$10 to $50 million—equitySEC

How Ainos, Inc. compares in Biotechnology

  • Market cap$6 M · higher than 7% of 726
  • Revenue$0 M · higher than 17% of 648
  • Price / sales51.1× · lower than 17% of 339
  • Price / book0.8× · lower than 82% of 532
  • FCF yield-75.7% · higher than 14% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Ainos, Inc.🇺🇸$6 M———
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

How current the figures are

Market cap:
Oct 26, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 22, 2026

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Ainos, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Ainos, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Ainos, Inc.? Suggest a correction